Objectives: This study investigated the impact of neoadjuvant radiation therapy (XRT) on postoperative outcomes following pancreaticoduodenectomy for pancreatic cancer. Methods: The American College of Surgeons National Quality Improvement Program database was queried for the period 2005-2010 to assess complication rates following pancreaticoduodenectomy for pancreatic cancer. Two groups of patients were identified, comprising those who received neoadjuvant XRT and those who did not (control group). Results: A total of 4416 patients were identified, including 200 in the XRT group and 4216 in the control group. There were differences in patient characteristics between the groups, including in age, hypertension and bilirubin level. Despite the fact that weight loss was more common, median operative time was longer (423 min versus 368 min; P < 0.001), and vascular reconstruction was more commonly required (20.5% versus 8.4%; P < 0.001) in the XRT group. In addition, the XRT group had a shorter median hospital stay than the control group (9 days versus 10 days; P = 0.005). Mortality (3.0% versus 2.7%; P = 0.818) and morbidity (40.5% versus 37.6%; P = 0.404) rates were not influenced by neoadjuvant XRT. Blood transfusion rates were increased in the XRT group (13.0% versus 7.4%; P = 0.003). Severe complications were influenced by age >70 years, American Society of Anesthesiologists (ASA) class >2, preoperative sepsis, dyspnoea, weight loss, impaired functional status, peripheral vascular disease and operative time of >8 h. Conclusions: Neoadjuvant XRT is not associated with an increase in complications after pancreaticoduodenectomy.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death in the USA. 1 Surgical resection offers the only chance for cure. However, even after potentially curable surgery, 5-year survival rates remain dismal at <20%. 2 To improve survival, various treatment regimens and sequencing strategies incorporating chemotherapy and radiation therapy (XRT) have been studied. 3 As pancreatic cancer has a propensity for early local spread via perineural sheaths and lymphatic channels, there are anatomic and biological rationales for using regional XRT to treat this infiltrative pattern of spread. In support of this paradigm, chemoradiation therapy has been shown to slow local progression and improve survival in locally advanced pancreatic cancer. 4 Recently, XRT has been increasingly utilized as part of neoadjuvant therapy in patients with borderline resectable pancreatic cancer. Its utility in the treatment of initially resectable tumours is also being actively investigated. [5] [6] [7] The influence of preoperative XRT on postoperative surgical outcomes remains under debate. Radiation therapy induces inflammatory changes in the pancreatic parenchyma and peripancreatic tissues, resulting in the gradual disruption of natural tissue planes, which may make surgery more hazardous. 8 Radiation therapy combined with chemotherapy can also cause side-effects such as gastrointestinal toxicity that may debilitate the patient in the preoperative period, and these may increase surgical complication rates. However, there is some evidence that XRT may decrease pancreatic fistula rates after pancreaticoduodenectomy. 9, 10 To the present authors' knowledge, there has not been a close examination of nationwide outcome data on the impact of preoperative XRT on the safety of subsequent pancreaticoduodenectomy.
The primary aims of this study were to analyse the impact of preoperative XRT on morbidity and mortality rates following pancreaticoduodenectomy, and to identify predictors of severe postoperative complications.
Materials and methods
The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) is a nationwide initiative that generates prospective surgical outcome data for patients treated at participating hospitals in the USA. Trained clinical reviewers enter into a database information on patient demographics, medical comorbidities, preoperative laboratory values, surgical details and perioperative events. A systemic audit process has shown the accuracy and validity of the NSQIP data.
11 Examination of this nationwide database allows for the risk stratification of patients and meaningful comparisons of 30-day complication rates among hospitals. Surgical outcomes available for study include hospital length of stay (LoS), blood transfusion requirements during surgery and the 72-h postoperative period, and details of complications including 30-day postoperative mortality. As the present study institutions are participants in the ACS-NSQIP, the current authors have access to and requested use of the nationwide de-identified Participant User File (PUF).
The ACS-NSQIP database for 2005 to 2010 was queried to identify patients with the diagnosis of pancreatic neoplasm according to the International Classification of Diseases, 9th Revision (ICD-9) codes 157 and 157.1, 157.2, 157.3, 157.4, 157.8 and 157.9. Patients with malignant neoplasm of islets of Langerhans (ICD-9 code 157.4) were excluded. Next, using current procedural terminology (CPT) codes, patients with pancreatic cancer who underwent pylorus-preserving pancreaticoduodenectomy (CPT code 48153) or classic pancreaticoduodenectomy (CPT code 48150) were identified. The study population was then divided into two groups based on the use of XRT before pancreaticoduodenectomy.
Patient characteristics such as age, gender, race, medical comorbidities, use of neoadjuvant chemotherapy, preoperative blood transfusion, preoperative septic episodes, and laboratory test results were compared. Perioperative variables were evaluated to determine any differences between the two groups in terms of year of operation, types of pancreaticoduodenectomy performed, need for vascular reconstruction, operative time, intraoperative blood transfusion requirement and hospital LoS. Surgical outcomes were also determined to assess morbidity and mortality in each group. Severe complications were defined as organ space infection, sepsis, septic shock, reoperation, cardiac arrest and death; rates for each of these were also compared between the XRT group and the control group. Categorical variables were compared using the chi-squared test and Fisher's exact test as appropriate. Continuous variables were compared using Student's t-test or the Mann-Whitney U-test as appropriate.
Univariate analysis was performed to identify preoperative or perioperative variables that were associated with severe complications. Variables for which a P-value of < 0.1 was established on univariate analysis were included in a multivariate logistic regression model to define independent predictors of severe postoperative complications. Preoperative XRT was included in the logistic regression analysis as it was the main study variable. P-values of < 0.05 were considered to indicate statistical significance. Odds ratios (ORs) and 95% confidence intervals (CIs) were also calculated. spss Version 15.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis.
Results
A total of 9206 patients with the diagnosis of pancreatic cancer were identified in the ACS-NSQIP PUF. Patients with malignant neoplasms of the islet cells of Langerhans were excluded (n = 215). A total of 4416 patients underwent either pylorus-preserving (n = 1775) or classic (n = 2641) pancreaticoduodenectomy for pancreatic cancer. These patients were divided into two groups comprising, respectively, 200 (4.5%) patients who received radiation treatment within the 90 days prior to surgery (XRT group) and 4216 (95.5%) patients who did not (control group). Table 1 reports details of patient demographics and medical comorbidities. In comparison with the control group, patients in ; P = 0.037). In addition, preoperative chemotherapy within 30 days of surgery was given more frequently in the XRT group (28.5% versus 1.6%; P < 0.001). In terms of preoperative laboratory values, patients in the XRT group had lower median bilirubin (0.6 mg/dl versus 1.2 mg/dl; P < 0.001), serum glutamic oxaloacetic transaminase (SGOT) (33 IU/l versus 37 IU/l; P = 0.034) and alkaline phosphatase (123 IU/l versus 154 IU/l; P = 0.017). In addition, median blood urea nitrogen (BUN) (12 mg/dl versus 14 mg/dl; P < 0.001), creatinine (0.8 mg/dl versus 0.9 mg/dl; P < 0.001), white blood cell counts (5.6 ¥ 10 9 /l versus 7.2 ¥ 10 9 /l; P < 0.001) and platelet counts (230 ¥ 10 9 /l versus 264 ¥ 10 9 /l; P < 0.001) were lower in the XRT group than in the control group. Table 2 depicts perioperative details. The neoadjuvant use of XRT was found to have increased over the 5-year study period (P < 0.001). In 2010, neoadjuvant XRT was given to 7.5% of patients prior to pancreaticoduodenectomy performed for pancreatic cancer at NSQIP participating hospitals, reflecting an increase from 2.7% in 2006. Intraoperative blood transfusion rates were similar in the XRT group and the control group (P = 0.507). However, in the XRT group, surgery times were longer (median operative time: 423 min versus 368 min; P < 0.001), vascular reconstruction was required more frequently (20.0% versus 8.3%; P < 0.001), and classic pancreaticoduodenectomy was more commonly performed (74.0% versus 59.1%; P < 0.001). Despite the apparent increase in operative magnitude, hospital LoS was shorter in the XRT group (median LoS: 9 days versus 10 days; P = 0.005). Table 3 details the comparison of surgical outcomes between the two groups. Mortality rates were 3.0% and 2.7% in the XRT group and control group, respectively (P = 0.818). Overall morbidity rates were not influenced by preoperative XRT (40.5% Length of hospital stay, days, median Ϯ SD 9 Ϯ 9 1 0 Ϯ 11 0.005 CPT, current procedural terminology; SD, standard deviation. versus 37.6%; P = 0.404). Severe complications occurred at similar rates in both groups (19.0% versus 21.4%; P = 0.414). In terms of specific complications, the only difference between the study groups concerned the rate of postoperative blood transfusion, which was required more frequently in the XRT group than in the control group (13.0% versus 7.4%; P = 0.003). In addition, in order to compare the impact of age differences between the two groups on rates of severe complications, groups were stratified by age (<50 years, 50-70 years, >70 years) for further analysis (Table 4) . Preoperative XRT did not influence rates of severe complications in any of the age groups (P = NS). In order to compensate for the lack of staging information in the NSQIP database, patients were grouped according to need for vascular reconstruction as a surrogate marker for vascular involvement by the tumour (Table 4 ). In patients who required vascular reconstruction, rates of severe complications were not influenced by preoperative XRT (35.0% versus 23.7%; P = 0.118). However, interestingly, in patients who did not require vascular reconstruction, a trend towards lower rates of severe complications emerged in those who received preoperative XRT compared with those who did not (15.0% versus 21.2%; P = 0.059). Univariate analysis showed 13 variables associated with severe complications (P < 0.10) ( Table 5 ). On multivariate logistic regression analysis, older age, American Society of Anesthesiologists (ASA) class of >2, preoperative weight loss, dyspnoea, preoperative sepsis, impaired functional status, history of peripheral vascular disease and a surgery time of >8 h emerged as independently associated with severe complications. Preoperative XRT was not found to be a significant predictor in either univariate or logistic regression analysis.
Discussion
This contemporary, multi-institution analysis of ACS-NSQIP data demonstrates that, although still uncommon, the use of neoadjuvant XRT in pancreatic cancer has increased steadily in recent years. Because pancreatic cancer is associated with early local and distant recurrences, even after potentially curative surgery, preoperative treatment with XRT in combination with chemotherapy has several theoretical advantages. 3 The neoadjuvant phase of the multimodal treatment allows early treatment of systemic micro-metastases and selection of those with favourable tumour biology and good performance status who would benefit the most from pancreaticoduodenectomy. 12 In support of this claim, Evans et al. reported that patients with resectable pancreatic cancer can achieve median survival of 34 months and 5-year survival of 36% with a clinical protocol consisting of neoadjuvant treatment with gemcitabine and 30-Gy XRT followed by pancreaticoduodenectomy. 7 The benefits of neoadjuvant therapy, however, may be overshadowed by potential systemic and local effects of irradiation that impact outcomes in the postoperative period. To address these issues, this study explored the relationship between neoadjuvant XRT and surgical complications.
The analysis indicated that morbidity and mortality rates in patients who had received neoadjuvant XRT were similar to those in patients who proceeded directly to surgery. Even when patients were stratified by age or need for vascular reconstruction, rates of severe complications were not affected by neoadjuvant XRT. This finding is supported by the literature. 13, 14 Spitz et al., 15 for example, found a complication rate of 24% in 41 patients who underwent surgery after chemoradiation treatment, in comparison with 21% in 19 patients who proceeded directly to surgery. However, the present study is unique in that it used a validated national database to specifically investigate the impact of neoadjuvant XRT on postoperative complications. The fact that vascular reconstruction was required more frequently suggests that borderline resectable tumours were more common in the XRT group. In addition, operative times were longer and postoperative blood transfusion was given more frequently in the XRT group. Despite the presence of these factors, which typically would increase the expected complication rates, the rates observed were similar to those in non-irradiated patients, and hospital stay was shorter in the XRT group. The present observation that postoperative blood transfusion rates were increased in the XRT group raises concerns over a potential deleterious impact on tumour recurrence and longterm survival. 16 However, the present study shows that safety of surgery is not compromised by neoadjuvant XRT.
On multivariate logistic regression analysis, neoadjuvant XRT did not influence rates of severe complications; rather, factors such as greater age, impaired functional status, preoperative sepsis, dyspnoea, weight loss, peripheral vascular disease, an ASA class of >2 and a long operative time were independently associated with the development of severe complications. Although association does not prove causation, an attempt to remedy these issues during and after XRT may improve surgical outcomes. Given the favourable outcomes observed in the XRT group, despite the technically more demanding operations performed in this group, it appears that the preoperative period benefits these patients. Further studies will be needed to determine the optimal recovery period between chemoradiation therapy and surgery to achieve the proper balance between tumour response, patient prehabilitation, and the onset of radiation-induced inflammatory changes.
A common major morbidity specific to pancreatic surgery is pancreatic leak. Several studies have suggested that XRT may reduce pancreatic leak by impairing pancreatic exocrine function and also by inducing fibrosis of the pancreatic gland, making it more amenable to suture placement. 9, 10 The standard ACS-NSQIP dataset does not document pancreatic leak as a separate outcome measure. However, potential surrogates for clinically relevant pancreatic leak, such as deep organ space surgical site infection, sepsis, septic shock, reoperation, cardiac arrest and death were available for analysis. The rates of these severe complications were similar between the two study groups. Data from the hepatopancreatobiliary (HPB)-specific NSQIP demonstration project introduced in 2011 suggests that deep organ space infection is only 55% sensitive for pancreatic fistula in the NSQIP database, which potentially explains these results (H. Pitt, personal communication, 2012). Further analysis from the HPB-NSQIP Collaborative may contribute towards the specific examination of the role of neoadjuvant XRT in pancreatic leak rates.
The present study adds to a growing body of surgical literature derived from national databases with third-party reporting of outcomes, which is unlike previously reported case series studies from specialist single institutions. There are, however, limitations to the current study that warrant mention. For instance, the differences in demographic findings between the two groups, such as in age, preoperative weight loss and BMI, may have affected surgical outcomes. Furthermore, the fact that preoperative use of chemotherapy is captured in the database only if it occurs within 30 days of surgery may have influenced the documented frequency of preoperative chemotherapy in this study. Most importantly, the lack of data on hospital setting and surgeon experience in the NSQIP database may have confounded the current findings because more difficult surgeries associated with locally advanced disease are more likely to have been performed at tertiary centres with specialized surgical expertise and multidisciplinary support.
Conclusions
Clearly, the decision on whether to treat a patient with pancreatic cancer with neoadjuvant chemoradiation therapy is complex. The main finding of this study, that the use of neoadjuvant XRT is not associated with increased complications after pancreaticoduodenectomy, is an important piece of information to be used in determining the optimal treatment strategy for patients with newly diagnosed pancreatic cancer. Further studies are needed to determine the appropriate role of neoadjuvant XRT, including patient selection, optimal dose, and sequencing with chemotherapy and surgery, in order to maximize its benefits.
